Trial Profile

Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with extensive-stage small-cell lung cancer: (JMTO LC 08-01) .

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amrubicin (Primary) ; Cisplatin; Irinotecan
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

22 Mar 2019 Status changed from active, no longer recruiting to completed.
14 Jul 2014 According to the University Hospital Medical Information Network - Japan, status changed from recruiting to active, no longer recruiting.
14 Jul 2012 Additional lead trial centre (Japan-multinational Trial Organization) added as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com